P2Y12-receptor-inhibiting antiplatelet strategies in acute coronary syndromes
| Autor: | Kurt Huber, Thomas Höchtl |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Acute coronary syndrome Prasugrel Hemorrhage 030204 cardiovascular system & hematology law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Cangrelor P2Y12 Randomized controlled trial law Internal medicine medicine Humans cardiovascular diseases 030212 general & internal medicine Acute Coronary Syndrome Evidence-Based Medicine Dose-Response Relationship Drug Maintenance dose business.industry Hematology medicine.disease Clopidogrel Treatment Outcome chemistry Drug Design Purinergic P2Y Receptor Antagonists Cardiology business Ticagrelor Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Hämostaseologie. 34:20-28 |
| ISSN: | 2567-5761 0720-9355 |
| DOI: | 10.5482/hamo-13-08-0044 |
| Popis: | SummaryAntiplatelet therapy in acute coronary syndromes is essential for preventing stent thrombosis and for reducing major adverse cardiovascular events. Treatment strategy has changed over the last years by frequent use of more active agents inhibiting the ADP mediated activation of platelets instead of clopidogrel, such as prasugrel and ticagrelor. Compared to clopidogrel these modern antiplatelet drugs showed a significant reduction of efficacy endpoints as well as an acceptable safety profile in large multicenter randomized trials (TRITON TIMI 38, PLATO). Going in with higher efficacy a generally higher bleeding risk of prasugrel could be reduced by optimizing the maintenance dose in elderly and underweight patients (TRILOGY-ACS). However even prasugrel and ticagrelor have shown a delayed onset of action in special patient populations (e.g. STEMI) suggesting that the optimal ADP inhibitor has not been found yet. Results of the CHAMPION PHOENIX trial indicate that cangrelor, an intravenous agent, might fulfill these high expectations of an ideal platelet inhibitor in the first hours of an ACS in special patient cohorts.This review summarizes the results of most important clinical studies investigating the novel P2Y12 receptor inhibiting antiplatelet drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|